KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Common Equity (2016 - 2025)

Historic Common Equity for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $503.9 million.

  • Halozyme Therapeutics' Common Equity rose 1131.25% to $503.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $503.9 million, marking a year-over-year increase of 1131.25%. This contributed to the annual value of $363.8 million for FY2024, which is 33411.25% up from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' Common Equity is $503.9 million, which was up 1131.25% from $332.7 million recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Common Equity high stood at $503.9 million for Q3 2025, and its period low was $65.8 million during Q1 2023.
  • Moreover, its 5-year median value for Common Equity was $249.2 million (2023), whereas its average is $244.1 million.
  • Its Common Equity has fluctuated over the past 5 years, first crashed by 7469.8% in 2023, then skyrocketed by 33411.25% in 2024.
  • Halozyme Therapeutics' Common Equity (Quarter) stood at $197.0 million in 2021, then decreased by 13.79% to $169.8 million in 2022, then plummeted by 50.64% to $83.8 million in 2023, then skyrocketed by 334.11% to $363.8 million in 2024, then surged by 38.51% to $503.9 million in 2025.
  • Its last three reported values are $503.9 million in Q3 2025, $332.7 million for Q2 2025, and $482.3 million during Q1 2025.